Candel Therapeutics (CADL) together with IDEA Pharma announced a strategic commercial partnership. Under this agreement, IDEA will provide strategic commercial input throughout the development and commercialization process for Candel’s lead asset, CAN-2409. This partnership comes at a pivotal time for Candel following positive phase 3 data for CAN-2409 in intermediate-to-high risk, localized prostate cancer, which showed a statistically significant improvement in disease-free survival with 30% decrease in disease recurrence and a statistically significant increase in pathological complete response rate in the 2-year post-treatment biopsies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics appoints Jaffee to RAB
- Candel Therapeutics Reports Positive Clinical Trial Results
- Promising Clinical Results and Strong Potential of Candel Therapeutics’ CAN-2409 Justify Buy Rating
- Candel Therapeutics: Promising Clinical Developments and Strong Buy Rating
- Candel Therapeutics reports Q4 EPS (40c), consensus (23c)